Filana Therapeutics, Inc. FLNA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -18.47% | -35.44% | -66.75% | -81.23% | -92.68% |
| Gross Profit | 18.47% | 35.44% | 66.75% | 81.23% | 92.68% |
| SG&A Expenses | -6.31% | -32.15% | -16.36% | -36.37% | -43.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.94% | -33.35% | -48.26% | -67.61% | -62.61% |
| Operating Income | 4.94% | 33.35% | 48.26% | 67.61% | 62.61% |
| Income Before Tax | 0.75% | 80.55% | 55.86% | 54.56% | 61.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.75% | 80.55% | 55.86% | 54.56% | 61.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.75% | 80.55% | 55.86% | 54.56% | 61.32% |
| EBIT | 4.94% | 33.35% | 48.26% | 67.61% | 62.61% |
| EBITDA | 5.67% | 34.06% | 48.87% | 68.57% | 62.72% |
| EPS Basic | 1.07% | 80.55% | 55.89% | 54.76% | 61.59% |
| Normalized Basic EPS | 1.07% | 33.43% | 49.39% | 69.19% | 63.05% |
| EPS Diluted | 1.07% | 80.43% | 55.89% | 54.67% | 61.59% |
| Normalized Diluted EPS | 1.07% | 33.43% | 49.39% | 69.19% | 63.05% |
| Average Basic Shares Outstanding | 0.32% | 0.00% | 0.10% | 0.43% | 0.69% |
| Average Diluted Shares Outstanding | 0.32% | 0.00% | 0.10% | 0.43% | 0.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |